Boston Scientific (NYSE:BSX) Sets New 52-Week Low – Here’s Why

Boston Scientific Corporation (NYSE:BSX) shares hit a new 52-week low on Tuesday . The company traded as low as $55.94 and last traded at $55.9820, with a volume of 5151806 shares trading hands. The stock had previously closed at $56.85.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research reports. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Wells Fargo & Company cut their price target on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. TD Cowen dropped their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a report on Monday, February 2nd. Finally, Citigroup dropped their target price on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Trading Down 1.5%

The firm has a 50-day moving average price of $67.06 and a 200-day moving average price of $84.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock has a market cap of $83.20 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently bought and sold shares of BSX. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Main Street Financial Solutions LLC grew its stake in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC grew its stake in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC grew its stake in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.